Health Law Alliance's existing guide, OptumRx Audit Defense: What Pharmacies Should Expect, covers the notice itself: the audit formats OptumRx uses, the discrepancy categories it cites, and the dispute deadline on the results letter. This article covers what comes next in an OptumRx PBM audit: how a preliminary finding becomes a final recoupment demand, what state law adds on top of OptumRx's own process, and what documentation actually moves a finding on appeal. The same documentation questions apply to 340B claims at contract pharmacies, covered separately in 340B Contract Pharmacy Audits: Duplicate Discount Risk. Large recoupment demands and network termination can both turn on how this stage is handled.
Preliminary and Final Findings Are Different Stages
OptumRx audits move through two distinct findings before a recoupment is finalized: a preliminary finding, issued after OptumRx reviews the documentation a pharmacy submitted in response to the audit notice, and a final finding, issued once the pharmacy's opportunity to respond to the preliminary finding has closed. Treating the two as interchangeable is the most common mistake pharmacies make. The preliminary stage is where new documentation still carries full weight, and California and Pennsylvania both require the auditor to take that response into account before issuing the final report. An audit appeal challenges the final finding, but the evidence that wins it is almost always the evidence submitted earlier, at the preliminary stage.
What State Law Requires Between the Two Findings
PBM audit appeal timing comes from state law rather than from OptumRx alone, and it varies by state. California's Business and Professions Code Section 4438 requires a preliminary audit report within 60 days of the audit's conclusion, gives the pharmacy at least 30 days to respond with supporting documentation, and requires the final report to issue no later than 120 days after OptumRx receives that response, with its own 30-day window for appealing that final report. Pennsylvania's Pharmacy Audit Integrity and Transparency Act (Act 169 of 2016), Section 301, follows a similar frame: a 60-calendar-day preliminary report, a 30-calendar-day pharmacy response window, and a final report within 60 calendar days of that response, with recoupment collection barred until the appeal period passes or the appeal process is exhausted. Both statutes treat the preliminary-report response as the pharmacy's first and most consequential filing. A pharmacy in a different state should confirm its own audit statute before assuming either timeline applies.
What to Submit, and When
The preliminary-report response is where documentation should be complete, not partial: the prior authorization record, the signed prescription in hard copy or electronic form, the delivery or pick-up signature log matched to the dispensing date, and the inventory purchase invoice tying the NDC and quantity back to the claim. Where OptumRx's finding relies on extrapolation, California's statute shows the evidence that counts: documentation validating the individual sampled orders, rather than a general objection to the extrapolation method. A finding that turns on acquisition cost or a MAC rate, rather than a documentation gap, calls for the pricing data covered in AWP, WAC, NADAC and MAC: Pharmacy Pricing Benchmarks Compared. Submitting that complete record at the preliminary stage is what the response windows above are built to allow.
Preserving the Record Through Escalation
Keep a dated copy of every document sent to OptumRx and received back, including the preliminary finding, the response, and the final report. California and Pennsylvania each tie a pharmacy's rights directly to those dates, making the pharmacy's own file the first place to check whether OptumRx met its own deadlines. Where an appeal does not resolve the finding and the matter moves toward network termination instead, that is a separate legal question, governed by the framework in Any Willing Provider Laws and PBM Network Exclusion rather than the audit statute above.
A pharmacy that waits for a final recoupment demand to start building its appeal has already missed the stage of the process where new documentation carries the most weight.
Why Early Legal Counsel Is Critical
It is critical that pharmacies promptly retain experienced healthcare defense counsel once an OptumRx audit moves from a preliminary finding toward a final recoupment demand. Early legal intervention can confirm which state deadlines actually apply, shape what evidence goes into the preliminary-stage record before it closes, avoid admissions that later undercut an appeal, and position the matter for escalation if OptumRx's own process falls short of what its state requires.
How Health Law Alliance Can Help
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
If OptumRx has issued a preliminary finding or a final recoupment demand, Health Law Alliance's PBM audit defense attorneys represent pharmacies through every stage of that process, including escalation beyond OptumRx's own appeal. Contact the firm for a free, confidential consultation before the response window closes.
